Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor Blanchette

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
Thrombosis and Haemostasis|March 31, 2017
Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentratesAlfonso Iorio, Kathelijn Fischer, Victor Blanchette, et al.
The Journal of Pediatrics|November 3, 2004
Clinical and cost implications of target joints in Canadian boys with severe hemophilia AMelissa Kern, Victor Blanchette, Ann Marie Stain, et al.
Journal of General Internal Medicine|July 18, 2014
Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia ALusine Abrahamyan, Andrew R Willan, Joseph Beyene, et al.
Clinical Genetics|February 22, 2019
PKD1L1-related situs inversus associated with sideroblastic anemiaShaina Rodriguez, Rajiv Chaturvedi, Victor Blanchette, et al.
Haematologica|March 2, 2016
Securing reimbursement for patient centered haemophilia care: major collaborative efforts are neededKarin C Berger, Brian M Feldman, Joan Wasserman, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Updating the Canadian hemophilia outcomes-kids life assessment tool (CHO-KLAT Version2.0)Nancy L Young, Cindy Wakefield, Tricia A Burke, et al.
Thrombosis Research|September 12, 2012
PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitorsGuy Young, Guenter Auerswald, Victor Jimenez-Yuste, et al.
Nature Reviews. Disease Primers|June 25, 2021
HaemophiliaErik Berntorp, Kathelijn Fischer, Daniel P Hart, et al.
Transfusion|November 18, 2003
Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIIIJohn Freedman, Margaret L Rand, Olive Russell, et al.
Pediatric Blood & Cancer|June 4, 2009
Relationships among bleeding severity, health-related quality of life, and platelet count in children with immune thrombocytopenic purpuraCindy E Neunert, George R Buchanan, Victor Blanchette, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Thrombosis and Haemostasis|March 31, 2017
Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentratesAlfonso Iorio, Kathelijn Fischer, Victor Blanchette, et al.
The Journal of Pediatrics|November 3, 2004
Clinical and cost implications of target joints in Canadian boys with severe hemophilia AMelissa Kern, Victor Blanchette, Ann Marie Stain, et al.
Journal of General Internal Medicine|July 18, 2014
Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia ALusine Abrahamyan, Andrew R Willan, Joseph Beyene, et al.
Clinical Genetics|February 22, 2019
PKD1L1-related situs inversus associated with sideroblastic anemiaShaina Rodriguez, Rajiv Chaturvedi, Victor Blanchette, et al.
Haematologica|March 2, 2016
Securing reimbursement for patient centered haemophilia care: major collaborative efforts are neededKarin C Berger, Brian M Feldman, Joan Wasserman, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Updating the Canadian hemophilia outcomes-kids life assessment tool (CHO-KLAT Version2.0)Nancy L Young, Cindy Wakefield, Tricia A Burke, et al.
Thrombosis Research|September 12, 2012
PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitorsGuy Young, Guenter Auerswald, Victor Jimenez-Yuste, et al.
Nature Reviews. Disease Primers|June 25, 2021
HaemophiliaErik Berntorp, Kathelijn Fischer, Daniel P Hart, et al.
Transfusion|November 18, 2003
Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIIIJohn Freedman, Margaret L Rand, Olive Russell, et al.
Pediatric Blood & Cancer|June 4, 2009
Relationships among bleeding severity, health-related quality of life, and platelet count in children with immune thrombocytopenic purpuraCindy E Neunert, George R Buchanan, Victor Blanchette, et al.
Pageof 6